---
title: "Castle Biosciences CEO Derek Maetzold sells USD 203,642 of common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296265511.md"
description: "Castle Biosciences CEO Derek J. Maetzold sold 1,100 common shares on August 14, 2026, at $30.02 per share, totaling approximately USD 203,642. He simultaneously exercised options for these shares at $2.39. Following the transaction, his direct stake decreased to 21,479 shares. Additionally, trusts linked to Maetzold sold 2,714 shares at the same price."
datetime: "2026-08-18T20:10:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296265511.md)
  - [en](https://longbridge.com/en/news/296265511.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296265511.md)
generator: "portal-rs"
---

# Castle Biosciences CEO Derek Maetzold sells USD 203,642 of common shares

-   Castle Biosciences CEO Derek J. Maetzold sold 1,100 shares on Aug. 14, 2026 at USD 30.02. \* He exercised options for 1,100 shares at USD 2.39 on the same day. \* Directly held stake fell to 21,479 shares following the transactions. \* Trusts linked to Maetzold also sold shares at USD 30.02, including 2,714 shares in the Maetzold Descendants 2020 Trust. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-057642), on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CSTL.US](https://longbridge.com/en/quote/CSTL.US.md)

## Related News & Research

- [238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC](https://longbridge.com/en/news/296578673.md)
- [Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26](https://longbridge.com/en/news/294868688.md)
- [Castle Biosciences CEO Derek Maetzold disposes of $202,507 in common shares](https://longbridge.com/en/news/294253874.md)
- [Consulting's race to become AI native](https://longbridge.com/en/news/296676838.md)
- [3 Next-Gen AI Stocks That 3G Capital Bought in Q2](https://longbridge.com/en/news/296496173.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**